Form 4: Abeona Therapeutics Director Acquires Shares Through Vesting

Abeona Therapeutics director Michael Amoroso acquired 36,101 shares of common stock through vesting of restricted stock.

Summary

• Michael Amoroso, a director at Abeona Therapeutics, acquired 36,101 shares of common stock on January 31, 2025.
• The shares were acquired through the vesting of restricted stock.
• The acquisition price was $0.00 per share.
• Following the transaction, Mr. Amoroso directly owns 180,466 shares of Abeona Therapeutics common stock.
• The restricted stock will fully vest on January 31, 2026.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock vesting for a director, which is generally viewed as a neutral to slightly positive event as it aligns management with shareholder interests.

Positives

• The vesting of restricted stock indicates a long-term commitment by the director.
• The increase in direct ownership aligns the director's interests with those of shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they acquire or dispose of company stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• This type of filing is standard practice for publicly traded companies in the US.
• Similar filings are made by directors and officers of other companies when they receive stock grants or exercise options.
• The vesting schedule is typical for restricted stock grants.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it increases the director's stake in the company.

Key Dates

Keywords

Abeona Therapeutics, Director, Michael Amoroso, Stock Acquisition, Share Vesting, Beneficial Ownership, Restricted Stock